Licensing · Global (LMICs) · Announced 10 Jun 2025
AriBio → Arcera Life Sciences
AriBio licensed oral Alzheimer's candidate AR1001 to Arcera's Acino for Latin America, the Middle East, Southern Africa, Ukraine and parts of Eurasia, in a deal valued at an estimated US$600m; Phase 3 data in Nov 2026 were mixed.
Parties: AriBio (South Korea) → Arcera Life Sciences (Acino) (United Arab Emirates)
- Deal type
- Licensing
- Value
- $600m
- Territory
- Latin America, the Middle East, Southern Africa, Ukraine and selected Eurasian countries
- Therapeutic area
- CNS / Neurology
- Asset
- AR1001
- Announced
- 10 Jun 2025
Our analysis
Why this matters
On 10 June 2025, South Korea's AriBio signed exclusive licensing and supply agreements with Acino, the Swiss company that is part of Abu Dhabi-based Arcera (established by ADQ), for AR1001. AR1001 is an investigational once-daily oral PDE5 inhibitor for early Alzheimer's disease. Arcera gets exclusive commercialisation rights in Latin America, the Middle East, Southern Africa, Ukraine and selected Eurasian countries, and AriBio will manufacture and supply the product. The deal is estimated at US$600 million across development, launch and commercialisation, contingent on milestones. The Korea Development Bank facilitated it.
The asset has since been tested. On 16 November 2026, AriBio reported topline results from the Phase 3 POLARIS-AD trial (1,535 patients, 13 countries, 52 weeks). The overall population missed the primary endpoint: the CDR-SB difference was −0.11 versus placebo (p=0.4015). The prespecified monotherapy group (n=604, patients not on cholinesterase inhibitors or memantine) met it, with −0.44 (p=0.0266). AriBio plans to discuss next steps with the FDA and has given no filing timeline.
The full analysis is free to read with a work email on this page.
Source: Arcera press release; MedEdge MEA; AriBio Phase 3 release (GlobeNewswire, 16 Nov 2026)